JPMorgan Flags Sharp Divergence: Bitcoin and Gold Flows
A JPMorgan analysis shows a striking split in ETF flows since late February, with Bitcoin ETFs drawing money while go...
Why Index Level Matters In Investing
This paragraph outlines why the index level matters for investors, including potential effects on timing and risk assessment, with a concise takeaway.
24,567 articlesGarmin, Quantumscape, Synaptics: Three Quiet Tech Plays
Garmin, Synaptics, and QuantumScape blend device hardware, AI-ready tech, and next-gen batteries in a low-profile tri...
Apple’s 108% Run Up Stuns Markets in 2026 Rally Wave
Apple’s stock has climbed 108% over five years, signaling a rare blend of device strength, services expansion, and ca...
Wells Fargo Sets $230 Target on DOV as Recovery Gains Steam
Wells Fargo lifts Dover with a $230 target as Q4 2025 results point to accelerating growth and improving margins. The...
Tulsi Gabbard Won’t Whether Question Tests Markets
A high-stakes Senate hearing over Iran policy put the spotlight on intelligence briefings and political risk. The key...
Seattle Passed Workers More: Gig-Worker Pay Law Backfires
A Seattle wage rule for gig-delivery drivers raised base pay, but researchers say monthly take-home barely rose as dr...
Morgan Stanley Making Move: Bank Targets Spot BTC ETF
Morgan Stanley files an amended S-1 for MSBT, signaling a concerted push to launch a spot Bitcoin ETF and disrupt the...
Indian Ocean Base Targeted Sparks Global Markets and Budgets
Iran's missile strike on Diego Garcia targets a pivotal U.S.-UK facility in the Indian Ocean, triggering a transregio...
BitGo Brings OTC Prediction Market Access via Susquehanna
BitGo expands institutional access by enabling OTC entry to prediction markets through a new alliance with Susquehann...
Morgan Stanley Raises Planet Target to $35 Amid AI Push
Morgan Stanley boosted its price target on Planet Labs to $35, citing rising defense and intelligence demand and a ro...
Wall Street Cuts Mosaic Again: UBS Slashes Target to $27
UBS cuts Mosaic’s price target to $27, citing squeezed phosphate margins from higher sulfur and input costs, as Wall ...
Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status